Key result
Natalizumab reduces rates of relapse and disease progression in multiple sclerosis, but its use is restricted due to the risk of progressive multifocal leukoencephalopathy.
Why the study?
Does natalizumab improve outcomes in patients with relapsing-remitting multiple sclerosis who have failed first-line treatments?
Population
30-year-old woman with relapsing-remitting multiple sclerosis after several first-line treatments have failed
Design
Case_report
Authors
Loading...
May support use after first-line failure in relapsing-remitting multiple sclerosis; leaves open PML risk stratification in larger cohorts.
Case Report (n=1)
Does natalizumab improve outcomes in patients with relapsing-remitting multiple sclerosis who have failed first-line treatments?
Natalizumab is a treatment option for relapsing-remitting multiple sclerosis but its use is restricted due to the risk of progressive multifocal leukoencephalopathy.
Richard M. Ransohoff (2007) conducted a case report in Relapsing-remitting multiple sclerosis (n=1). Natalizumab was evaluated. Natalizumab reduces rates of relapse and disease progression in multiple sclerosis, but its use is restricted due to the risk of progressive multifocal leukoencephalopathy.